CareDx, Inc. (FRA:1K9)
Germany · Delayed Price · Currency is EUR | Market Cap | 820.73M -32.4% |
| Revenue (ttm) | 305.12M +14.5% |
| Net Income | 60.05M |
| EPS | 1.04 |
| Shares Out | n/a |
| PE Ratio | 13.67 |
| Forward PE | 18.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 11 |
| Open | 16.79 |
| Previous Close | 16.76 |
| Day's Range | 16.79 - 16.79 |
| 52-Week Range | 9.83 - 23.42 |
| Beta | n/a |
| RSI | 51.72 |
| Earnings Date | Feb 24, 2026 |
About CareDx
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ... [Read more]
News
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells
In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profit...
CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy - Slideshow
2026-02-12. The following slide deck was published by CareDx, Inc.
CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript
CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy February 12, 2026 10:00 AM...
CareDx Announces Clinical Validation Results for AlloHeme, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthc...
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx to Present AlloHeme Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthc...
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026
The CEO of this leading medical diagnostic company sold shares throughout multiple days in January. But the manner in which the shares were sold shouldn't concern investors.
CareDx President and CEO Sells 19,000 Shares for $412,000
This transplant diagnostics specialist saw a notable insider sale amid a year of modest share price decline and ongoing product innovation.
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ —, a leading precision medicine company focused on the discovery, development, and commercialization of clinica...
Insider Sell: Hanna John Walter JR Sells Shares of CareDx Inc (CDNA)
Insider Sell: Hanna John Walter JR Sells Shares of CareDx Inc (CDNA)
Implied Volatility Surging for CareDx Stock Options
Investors need to pay close attention to CareDx stock based on the movements in the options market lately.
CareDx Preliminary Q4 Revenue Up 25%
(RTTNews) - CareDx, Inc. (CDNA) reported preliminary fourth quarter revenue of approximately $108 million, an increase of 25% year-over-year; testing services revenue of approximately $78 million, an ...
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthc...
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx and 10x Genomics to Launch ImmuneScape Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value health...
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healt...
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinica...
CareDX Has Reached An Inflection Point, But Regulatory Risks Remain (Upgrade)
CareDx Provides Notice of Proposed Derivative Settlement
CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JEFFREY EDELMAN, JAY...
CareDx Provides Notice of Proposed Derivative Settlement
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT NORTHERN DISTRICT...
Crypto.com partners with ERShares and Signal Markets on prediction market intelligence platform
Crypto.com | Derivatives North America (CDNA), a CFTC-registered exchange and clearinghouse affiliated with Crypto.com, has announced a strategic collaboration with … Continue reading The post Crypto....